Nam Bui retweeted
SCI member Nam Bui and Greg Charville discuss the importance of next-generation sequencing in #sarcoma. bit.ly/3t2CN7V @NamBuiMD @Greg_Charville #PrecisionMedicine
Nam Bui retweeted
I am proud that Stanford is leading the way in sarcoma research and treatment. #SarcomaAwarenessMonth @NamBuiMD bit.ly/3NVyeUu
Nam Bui retweeted
#Biomarkers of response are crucial in treating patients with #SoftTissueSarcomas. Bui et al evaluate circulating tumor DNA as a biomarker and find that it represents a promising biomarker for monitoring treatment response. bit.ly/3NNqUJu @NamBuiMD @everettmoding
Nam Bui retweeted
Our new study with @NamBuiMD and Kristen Ganjoo tracking #ctDNA in patients with #sarcoma treated with #immunotherapy and #cryotherapy is online now @CCR_AACR. doi.org/10.1158/1078-0432.CC…
Test your knowledge with our Case of the Week!
History: Breast cancer patient undergoing neo-adjuvant chemotherapy presents with tongue changes.
#MedTwitter #CPCcasereports @OncologyAdvance @UPMCHillmanCC @breastoncdoc
Nam Bui retweeted
Got to meet up after today’s #ASCO22 sessions with my former @UCSDCancer co-fellows who are now academic GI Onc at UCSD and academic sarcoma onc at Stanford. So great to see old friends in person after many years apart! @NamBuiMD
Discuss your next case report with Dr. Nam Bui at ASCO. Stop by Elsevier booth 21127 today at 11:30 am CDT. @NamBuiMD #ASCO22 @OncologyAdvance #OpenAccess #oncology
Stop by booth 21127 in the ASCO exhibit hall and meet the Editor-in-Chief of CPC: Case Reports! @NamBuiMD #ASCO22 @OncologyAdvance #oncology #OpenAccess
Excited to announce that Current Problems in Cancer & our #OpenAccess companion title, Current Problems in Cancer: Case Reports are on Twitter!
Follow @CurrProbCancer for updates on the latest scientific developments published in our journals.
#CurrProbCancer #CPCcasereports
Nam Bui retweeted
Our new CME Series on #RareCancers launches this Friday! Don't miss out on this 1-day, comprehensive & complimentary update on #ThyroidCancer and #Sarcomas. rarecancersupdates.com @jordanberlin5 @Blomainiac @candace_haddox @NamBuiMD @ThereSuhGuo
Great case of precision medicine in a #LMS patient we treated. ALK fusion detected, however no response to crizotinib. Patient underwent other chemo, VEGF tx with progression, considered for hospice. Decided to try 2nd gen ALK inhibitors, alectinib, with robust response.
This case study from @StanfordMed illustrates why I wish everyone with #leiomyosarcoma could get genomic testing. A woman with a FN1-ALK fusion had a good response to alectinib and lorlatinib. pubmed.ncbi.nlm.nih.gov/3424… #sarcoma
Major decision and highly controversial accelerated approval in Alzheimer's. Two phase 3 studies that were stopped midway due to futility but a subgroup analysis of one trial showed benefit.
nytimes.com/2021/06/07/healt…
1
First time I've seen a RCT in dogs published in CCR! And no this is not an animal model, this is actually pet dogs with osteosarcoma!
Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs clincancerres.aacrjournals.o…
4
Point #2 is critical. We have a lot of multi histology single arm Phase II likely bc easier to accrue/complete in single centers. But with ORR being uncommon in sarcoma, how do we interpret this variable PFS data in context of existing agents? How does this change practice?
discussion #2🌟summary by @VKeedySarcomaMD
☑️eribulin+gem is tolerable, PFS 12 wks ~72% in LMS/LPS (but single arm)
☑️gem/tax/olara is not better than gem/tax, ? ⬆️OS in LMS w prior olara
☑️cabazitaxel for dLPS - PFS 12 wks 57%
#ASCO21 #womeninsarcoma @VUMC_Cancer
2
Very insightful piece about the use of PD-L1 as a biomarker in immunotherapy trials and how a "bottoms-up" approach has led it to be used as more of a tool to increase market share rather than a strong predictor of benefit for patients.
How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy annalsofoncology.org/article…
1
❗️LAG-3 antibody + Nivolumab mPFS benefit of 10.1 vs 4.6 months vs Nivolumab alone (HR 0.75, p=0.0055). Large Phase III with 714 melanoma patients. Is this finally the first new effective checkpoint target beyond CTLA-4/PD-1?! Pending ORR/OS
ascopost.com/news/may-2021/f… via @ascopost
2
Wow! Google is releasing an AI-powered skin lesion analyzer, direct to consumer.
Using AI to help find answers to common skin conditions @google blog.google/technology/healt…
1
FYI for everybody who's Outlook suddenly became borked today with blank messages. I spent 30 minutes trying to repair, reinstall, etc. 😡
We’re investigating an issue with email message visibility in Outlook. Outlook on the web appears to be unaffected. More details can be found under EX255650 in the admin center.
1
1/ For those interested in drug development (and have some time on your hands!), look at sponsor presentations in link below at ODAC review of accelerated approvals for IO with failed confirmatory trials. (Search for "presentations" at the bottom table)
fda.gov/advisory-committees/…
2/ Most of the accelerated approvals were based off single arm IO trials with some activity in ORR and DOR. Confirmatory trial strategies were wildly different!
• Different patient population entirely (urothelial AA in platinum ineligible, confirm trial in platinum eligible)
1
1





















